View Post

Biomarkers for Early-Stage Invasive Breast Cancer Clinical Practice Guidelines (ASCO, 2019)

In In The News by Barbara Jacoby

Source: American Society of Clinical Oncology From: medscape.com The American Society of Clinical Oncology (ASCO) published recommendations on the use of biomarkers for decision making regarding adjuvant systemic treatment for women with early-stage invasive breast cancer in April 2016.[1] In August 2017 and August 2019, ASCO released focused updates of these guidelines.[2,3] The combined recommendations are summarized below. ASCO advises …

View Post

Final Results of the KRISTINE Trial in HER2-Positive Breast Cance

In Clinical Trials by Barbara Jacoby

By: Dave Levitan From: cancernetwork.com Treatment for HER2-positive breast cancer with trastuzumab emtansine (T-DM1) plus pertuzumab yielded a higher risk of event-free survival (EFS) events compared with trastuzumab, pertuzumab, and chemotherapy, according to a phase III trial. There was a similar risk of invasive disease–free survival (IDFS) events, though, suggesting that chemotherapy may be unnecessary in some patients. The standard …

View Post

Evaluating Use of Bone-Modifying Agents to Treat Skeletal-Related Events in Cancer

In In The News by Barbara Jacoby

By: Laura Joszt From: ajmc.com Skeletal-related events are frequent complications in patients with cancers. Two abstracts analyzed the use of bone-modifying agents in patients with newly diagnosed multiple myeloma and breast cancer. Skeletal-related events are frequent complications in patients with cancers. Two abstracts presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting analyzed the use of bone-modifying …

View Post

TAPUR: When Chemo Stops Working

In Clinical Trials by Barbara Jacoby

From: ksat.com MIAMI, Fla. (Ivanhoe Newswire) – Finding out you have cancer is scary enough. But if the doctor says it’s stage 4 then you know it’s life-threatening. A nationwide study changed the life of one woman who was told she was ready for hospice. Anita Shangvi has battled breast cancer since 2007. Shangvi said, “First recurrence was 2011.” Then three …

View Post

PBM practices harm care for cancer patients, oncology professional group says

In In The News by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com In a position statement, ASCO said PBM practices can result in medication dispensing errors, harm physicians’ ability to treat patients and drive up costs. One of the largest cancer organizations in the United States has joined the chorus of criticism of the pharmacy benefit manager industry. The American Society of Clinical Oncology – a professional …

View Post

ASCO Endorses Some Complementary Therapies in Breast Cancer

In In The News by Barbara Jacoby

By: Roxanne Nelson, BSN, RN From: medscape.com Many cancer patients use alternative medicine, including supplements, massage therapy, yoga, and accupuncture, while undergoing conventional cancer care. Such therapies are usually acceptable, but patients must be discuss such therapies with their oncologist, because interactions may occur. That appears to be the take-home message from the recent move by the American Society of Clinical …

View Post

Most Women With Early Stage Breast Cancer Can Forgo Chemotherapy When Guided by a Diagnostic Test

In In The News by Barbara Jacoby

From: asco.org ASCO Perspective “This study, which never would have happened without federal funding for cancer research, will transform care immediately, and for the better. These data provide critical reassurance to doctors and patients that they can use genomic information to make better treatment decisions in women with early-stage breast cancer. Practically speaking, this means that thousands of women will be …

View Post

FDA chief outlines new ways to speed cancer drug approvals

In In The News by Barbara Jacoby

By: Julie Steenhuysen From: reuters.com The U.S. Food and Drug Administration is taking steps to streamline the approval process for cancer drugs, reviewing clinical trial data up front to make sure applications companies submit are complete. The new approach, outlined on Saturday in a speech by FDA commissioner Dr. Scott Gottlieb at the American Society of Clinical Oncology (ASCO) meeting in …

View Post

A Biotech Executive Faces End-Stage Cancer As A Patient

In In The News by Barbara Jacoby

By: Matthew Herper From: forbes.com For years, Michael Becker was one of the drug executives navigating swarms of cancer doctors at the annual meeting of American Society of Clinical Oncology, where 40,000 people gather every year to talk about the hottest cancer-killing drugs. This year he came back, but it was very different. This time he spoke to an audience of …

View Post

Consider This a Warning on Cancer-Drug Combos

In In The News by Barbara Jacoby

By: Max Nisen From: bloomberg.com The hype over these treatments has dramatically outpaced delivery. The pharmaceutical industry believes that the lucrative future of cancer treatment lies in combining immune-boosting medicines with other drugs to boost their effectiveness. But that future is still a ways off, and the present is pretty ugly. It’s something to keep in mind as one of the year’s biggest cancer …